Join Now

Utah Life Sciences News & Events

CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center

January 11, 2022

CenExel Clinical Research, Inc., announced the acquisition of Rocky Mountain Movement Disorders Center’s clinical research site operations. CenExel Rocky Mountain Clinical Research (“CenExel RMCR”) is a leading movement disorders-focused research facility in Denver, with experience spanning more than 100 clinical trial studies. The primary indications served by CenExel RMCR include Parkinson’s Disease, Huntington’s Disease, Essential Tremor, and other movement disorders.

This acquisition complements CenExel’s leading CNS trial capabilities and further extends CenExel’s reach into additional therapeutic indications within Neurology. CenExel RMCR is led by Dr. Rajeev Kumar, who has more than 20 years of CNS-focused clinical trial research and medical practice experience. 

The CenExel Centers of Excellence network now comprises 13 of the most proficient clinical research sites in the country, with special emphases on Neurology, Pain, Psychiatry, Vaccines/Immunology, Dermatology, Ethnic-bridging, Sleep studies, and Clinical Pharmacology. Each of the CenExel research units has outstanding records of assisting pharmaceutical sponsors with protocol development, study design, and conducting Phase I-IV trials to develop new therapeutics for improved patient care.

CenExel RMCR will take advantage of the CenExel network’s fully integrated and collaborative processes, which include centralized budgeting, business development, contracting, SOPs, and quality management, among others.

“The CenExel RMCR team has consistently delivered exceptional clinical trial recruitment and data quality, while helping patients with serious neurological conditions achieve their life goals,” said Tom Wardle, CenExel CEO. “The partnership with Dr. Kumar and the entire CenExel RMCR team will further elevate the Neurology strength of the CenExel network.”

“CenExel RMCR will continue to be a leader in the movement disorders therapeutic area, providing solutions for families and their loved ones,” said Dr. Kumar, Founder and Principal Investigator at CenExel RMCR. “We’re excited to leverage CenExel’s site network infrastructure and best practices to expand CenExel RMCR’s capabilities and serve more patients impacted by such neurological conditions together.”

CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has enthusiastically pursued both organic growth and acquisitions of state-of-the-art research centers around the U.S. The mission of CenExel is to work with trial Sponsors and Contract Research Organizations to reduce costs and development times for innovative therapies which may advance patient care.

Objective, Investment Banking & Valuation acted as exclusive sell-side financial advisor to CenExel RMCR in the transaction.

Media Contact: media@CenexelResearch.com